QUOTE AND NEWS
Market Intelligence Center  Jul 17  Comment 
After closing Wednesday at $23.07, Bruker BioSciences (BRKR) presents an attractive opportunity to get a 4.07% return in just 65 days, which is an annualized return of 22.86% (for comparison purposes only). To enter this trade, sell one Sep. '14...
TheStreet.com  Jul 8  Comment 
NEW YORK (TheStreet) -- RATINGS CHANGES AIMCO was upgraded at UBS to buy from neutral. Valuation call with a 12-month price target of $36, UBS said. Bruker was downgraded at ISI Group to neutral from buy. Valuation call, based on a 12-month...
DailyFinance  Jun 25  Comment 
Bruker Corporation (NASDAQ: BRKR) today announced that it has received clearance from the China Food and Drug Administration (CFDA) to market and sell its IVDMALDI BiotyperSystem as a medical device in China for the...
Market Intelligence Center  Jun 24  Comment 
A covered call identified by MarketIntelligececenter.com's patented algorithm on Bruker BioSciences (BRKR) could yield about 5.29% (10.78% annualized, for comparison purposes only) in 179 days. Pair a long position in the stock with the Dec. '14...
StreetInsider.com  Jun 19  Comment 
UPGRADES UBS raises Starbucks (Nasdaq: SBUX) from Neutral to Buy. Wells Fargo boosts Bruker (Nasdaq: BRKR) from Market Perform to Outperform and adjusts its price target from $21 to $22 up to $25 to $27. Click Here for more color. Canaccord...
TheStreet.com  Jun 19  Comment 
NEW YORK (TheStreet) -- Wells Fargo upgraded Bruker  to "outperform" from "market perform." The firm said the company appears willing to make a major overhaul to turn the business around.  The stock was up 2.25% to $23.60 in pre-market...
Market Intelligence Center  Jun 19  Comment 
Bruker BioSciences (BRKR) presents a trading opportunity that offers a 4.51% return in just 93 days. A covered call on Bruker BioSciences at the $22.50 level expiring on Sep. '14 offers an assigned return rate of 4.51% or 17.68% annualized. This...
SeekingAlpha  May 8  Comment 
Bruker Corporation (BRKR) Q1 2014 Results Earnings Conference Call May 7, 2014; 04:45 p.m. ET Executives Frank Laukien - President & Chief Executive Officer Charlie Wagner - Executive Vice President & Chief Financial Officer Joshua...
Market Intelligence Center  Apr 28  Comment 
For a hedged play on Bruker BioSciences (BRKR), MarketIntelligenceCenter.com’s option-trade picking algorithms recommend the Sep. '14 $20.00 covered call for a net debit in the $18.97 area. That is also the break-even stock price for the covered...
DailyFinance  Apr 7  Comment 
MANCHESTER, UNITED KINGDOM -- (Marketwired) -- 04/07/14 -- Epistem Holdings Plc (LSE:EHP), Manchester, UK, the biotechnology and personalized medicine company, today announced the successful installation of the Bruker Xtreme Imaging System within...




 
TOP CONTRIBUTORS

Bruker Bioscience manufactures scientific instruments for companies in life science, pharmaceutical, biotechnology, clinical and molecular diagnostics research, as well as in materials and chemical analysis. It develops products that utilize magnetic resonance technologies, mass spectrometry technologies, gas chromatography technologies, X-ray technologies, spark-optical emission spectroscopy, atomic force microscopy, stylus and optical metrology technology and infrared and Raman molecular spectroscopy technologies. They also manufacture superconducting materials and devices. Bruker Bioscience is a global company, but primarily sells it products in the Americas, Europe, and Asia. Due to the capital intense nature of its products customers may defer spending in tough economic years or to the last part of the year, leading to seasonality and unpredictable revenues.[1]

Business Growth

For 2010 the company reported revenue of $1,304.9 million, up 17.1% as compared to 2009. This increase was due to revenues attributable to recent acquisitions, increases in sales of its core technologies, particularly in magnetic resonance, X-ray and mass spectrometry, and an increase in demand for its low temperature superconducting wire.[1]

Trends and Forces

Bruker's revenues can fluctuate according to capital spending patterns of customers

Bruker's customers often stock up on lab consumables and equipment at the end of the year, when funding is abundant (for example, NIH funding is distributed to labs towards the end of the calendar year). They may also defer the purchase of capital intensive equipment in slow years such as the 2008 financial crisis. Bruker's revenues thus fluctuate throughout the year and are strongest in the last quarter of the calendar year. NIH funding is not completely stable, either - economic pressures may result in a stagnation of NIH funding, which has been growing at 2-3% in the past few years, but is not expected to increase in the near future. Bruker's customers from academic and government research labs are directly affected by the limitations of NIH grant funding; a lack of funding results in fewer laboratory product and equipment purchases and adversely affects Bruker's sales revenues.[1]

Competition

Bruker competes with many companies that have signifcantly more financial, technical, and marketing capabilities. To be successful it must create products that can compete based on technolgy, speed to market, and cost. Some of its toughest competitors include[1]:



References

  1. 1.0 1.1 1.2 1.3 Bruker BioSciences 2011 10k
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki